Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/6329 |
| _version_ | 1797554997269889024 |
|---|---|
| author | Alex Friedlaender Alfredo Addeo Alessandro Russo Vanesa Gregorc Diego Cortinovis Christian D. Rolfo |
| author_facet | Alex Friedlaender Alfredo Addeo Alessandro Russo Vanesa Gregorc Diego Cortinovis Christian D. Rolfo |
| author_sort | Alex Friedlaender |
| collection | DOAJ |
| description | Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanced and metastatic NSCLC. In particular, oncogenic drivers have indeed transformed the therapeutic algorithm for NSCLC. Nearly 25% of patients are diagnosed in an early stage when NSCLC is still amenable to radical surgery. In spite of this, five-year survival rates for fully resected early stage remains rather disappointing. Adjuvant chemotherapy has shown a modest survival benefit depending on the stage, but more than half of patients relapse. Given this need for improvement, over the last years different targeted therapies have been evaluated in early-stage NSCLC with no survival benefit in unselected patients. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents opened the way for a novel era in early stage NSCLC treatment. In this review, we will discuss the current landscape of targeted therapeutic options in early NSCLC. |
| first_indexed | 2024-03-10T16:41:00Z |
| format | Article |
| id | doaj.art-a347b93b7925407b925e2947529701d5 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:41:00Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a347b93b7925407b925e2947529701d52023-11-20T12:04:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-012117632910.3390/ijms21176329Targeted Therapies in Early Stage NSCLC: Hype or Hope?Alex Friedlaender0Alfredo Addeo1Alessandro Russo2Vanesa Gregorc3Diego Cortinovis4Christian D. Rolfo5Oncology Department, University Hospital of Geneva, 1205 Genève, SwitzerlandOncology Department, University Hospital of Geneva, 1205 Genève, SwitzerlandMedical Oncology Unit, A.O. Papardo, 98158 Messina, ItalyDepartment of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, 20132 Milan, ItalySC Medical Oncology, Azienda Socio Sanitaria Territoriale (ASST) H S Gerardo Monza, 20900 Monza, ItalyThoracic Oncology Department and Early Phase Clinical Trials Section, School of Medicine, University of Maryland, Baltimore, MD 20742, USANon-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanced and metastatic NSCLC. In particular, oncogenic drivers have indeed transformed the therapeutic algorithm for NSCLC. Nearly 25% of patients are diagnosed in an early stage when NSCLC is still amenable to radical surgery. In spite of this, five-year survival rates for fully resected early stage remains rather disappointing. Adjuvant chemotherapy has shown a modest survival benefit depending on the stage, but more than half of patients relapse. Given this need for improvement, over the last years different targeted therapies have been evaluated in early-stage NSCLC with no survival benefit in unselected patients. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents opened the way for a novel era in early stage NSCLC treatment. In this review, we will discuss the current landscape of targeted therapeutic options in early NSCLC.https://www.mdpi.com/1422-0067/21/17/6329NSCLCtargeted therapyearly stageEGFRALKosimertinib |
| spellingShingle | Alex Friedlaender Alfredo Addeo Alessandro Russo Vanesa Gregorc Diego Cortinovis Christian D. Rolfo Targeted Therapies in Early Stage NSCLC: Hype or Hope? International Journal of Molecular Sciences NSCLC targeted therapy early stage EGFR ALK osimertinib |
| title | Targeted Therapies in Early Stage NSCLC: Hype or Hope? |
| title_full | Targeted Therapies in Early Stage NSCLC: Hype or Hope? |
| title_fullStr | Targeted Therapies in Early Stage NSCLC: Hype or Hope? |
| title_full_unstemmed | Targeted Therapies in Early Stage NSCLC: Hype or Hope? |
| title_short | Targeted Therapies in Early Stage NSCLC: Hype or Hope? |
| title_sort | targeted therapies in early stage nsclc hype or hope |
| topic | NSCLC targeted therapy early stage EGFR ALK osimertinib |
| url | https://www.mdpi.com/1422-0067/21/17/6329 |
| work_keys_str_mv | AT alexfriedlaender targetedtherapiesinearlystagensclchypeorhope AT alfredoaddeo targetedtherapiesinearlystagensclchypeorhope AT alessandrorusso targetedtherapiesinearlystagensclchypeorhope AT vanesagregorc targetedtherapiesinearlystagensclchypeorhope AT diegocortinovis targetedtherapiesinearlystagensclchypeorhope AT christiandrolfo targetedtherapiesinearlystagensclchypeorhope |